Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not?
Accurate and specific MRD monitoring, coupled with the increasing development of targeted drugs, will give to clinicians an extraordinary opportunity to anticipate the treatment of AML relapse in the early phases eventually increasing drug efficacy and long-term outcome of the patients (visual abstract).
Authors
- Francesco Buccisano (ORCID: https://orcid.org/0000-0003-4320-9253)
- Ilaria Cerroni
- Federico Moretti (ORCID: https://orcid.org/0000-0001-6730-5296)
- Raffaele Palmieri (ORCID: https://orcid.org/0000-0003-2855-8121)
- Elisa Meddi
- Adriano Venditti
Institutions
- University of Rome Tor Vergata (IT)
Publication Details
- Journal
- Current Opinion in Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1097/cco.0000000000001197
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00